Related Experiment Video
Updated: May 9, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Aldosterone receptor antagonists: current perspectives and therapies
Jason L Guichard1, Donald Clark, David A Calhoun
1University of Alabama at Birmingham, Department of Medicine, Division of Cardiovascular Disease, Birmingham, AL 35294-2041 , USA.
Vascular Health and Risk Management
|July 10, 2013
Summary
Aldosterone, a hormone in the renin-angiotensin-aldosterone system, has newly discovered effects beyond the kidneys. Mineralocorticoid receptor antagonists show promise for treating various conditions, including hypertension and heart failure.
Area of Science:
- Endocrinology
- Cardiovascular Physiology
- Nephrology
Background:
- Aldosterone, a key hormone in the renin-angiotensin-aldosterone system, classically regulates kidney function.
- Emerging evidence reveals aldosterone's significant "off-target" effects in multiple organ systems.
- Both genomic and non-genomic actions of aldosterone are increasingly recognized, necessitating a revised understanding of its role.
Purpose of the Study:
- To review the biological actions of aldosterone and its receptor, the mineralocorticoid receptor.
- To explore the physiological and pathophysiological consequences of aldosterone signaling in the vasculature, CNS, heart, and kidneys.
- To summarize current research on mineralocorticoid receptor antagonists for various diseases.
Main Methods:
- Literature review of aldosterone's biological actions.
- Analysis of physiological and pathophysiological effects.
- Evaluation of clinical evidence for mineralocorticoid receptor antagonists.
Main Results:
- Aldosterone exerts effects beyond the kidneys, impacting cardiovascular and central nervous systems.
- Genomic and non-genomic pathways mediate aldosterone's diverse actions.
- Mineralocorticoid receptor antagonists are being investigated for primary aldosteronism, hypertension, heart failure, and CKD.
Conclusions:
- Aldosterone's role is more complex than previously thought, with significant implications for health and disease.
- Targeting the mineralocorticoid receptor offers therapeutic potential for a range of aldosterone-related conditions.
- Further research is warranted to fully elucidate aldosterone's actions and optimize antagonist therapies.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...